Neuroscientist
To reduce the scale and impact of dementia, we need to promote collaborative efforts and develop novel and affordable biomarkers for underserved and underrepresented populations.
Carlos is a postdoctoral researcher at the Latin American Brain Health Institute (BrainLat), Chile. He is researching new biomarkers using electroencephalography and mathematical models.
Tuomas Holopainen
Lead, encourage, empower, create, inspire
Carlos believes that to reduce the scale and impact of dementia, we need to promote collaborative efforts, and develop novel and affordable biomarkers for underserved and underrepresented populations.
Carlos is using mathematical models and electroencephalography to identify possible biomarkers of dementia. This can help in the development of novel therapeutic targets for neurodegenerative diseases.
As an Atlantic Fellow, Carlos aims to gain a deeper understanding of socioeconomic and biological risk factors of dementia. He wants to boost neuroscience research in Latin America, and reduce the impact of dementia in the region.
Dementia is facing rapid growth in Latin America, a highly diverse region underrepresented in dementia research. Region-specific and robust biomarkers are critical to provide a precise and early diagnosis of dementia.
Carlos holds a bachelor's degree in Biology (Universidad de Carabobo, Venezuela), and a PhD in Biophysics and Computational Biology (Universidad de Valparaíso, Chile). He is currently working as a postdoctoral researcher at the BrainLat Institute (Universidad Adolfo Ibáñez, Chile).
Carlos
a NoteHave ideas for global brain health or a collaboration? I would love to hear from you. Feel free to send an introductory note.